TOVX
Theriva Biologics, Inc.
$0.2417
-7.04%
$11.9M
No data for this timeframe.
Vol
Market Cap$11.9M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders4 funds
Inst. Value$111.2K
Inst. Activity3 buys / 1 sells
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases1
Recent Activity
Apr 17, 2026
SEC
Theriva Biologics announced positive results from its VIRAGE Phase 2b clinical trial, showing improved overall survival
8-K — Impact 7/10
Mar 12, 2026
SEC
Theriva Biologics reported financial results for 2025 and provided corporate updates, including licensing SYN-020 to Ras
8-K — Impact 6/10
Inst.
VANGUARD GROUP INC — DOUBLED
255,727 shares ($53.7K)
Inst.
MORGAN STANLEY — NEW
200,000 shares ($42.1K)
Jun 8, 2026
short_volume
Short Volume: TOVX — 58.9% short (0.4M / 0.6M)
Short: 382,604 | Exempt: 84,557 | TRF Vol: 649,763 | Short Ratio: 58.9% | Off-exchange volume (dark
Mar 12, 2026
Press
Theriva Biologics reported its 2025 financial results, highlighted by a $9.0 million contingent consideration charge tie
Impact 6/10
Price Targets
$2.50
+934.3% upside
Strong Buy
Current $0.2417
Low $1.00
Median $2.50
High $4.00
2 analysts
$1.00
$4.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 31, 2026 | Maxim Group | UPGRADE | Hold → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 | $-0.05 — $-0.05 | 97% YoY | 1 |
| Next Q | $-0.05 | $-0.05 — $-0.05 | 89% YoY | 1 |
| Current FY | $-0.20 | $-0.20 — $-0.20 | 90% YoY | 1 |
| Next FY | $-0.20 | $-0.20 — $-0.20 | 0% YoY | 1 |
Latest Reports
BULLISH
8-K
7/10
Theriva Biologics announced positive results from its VIRAGE Phase 2b clinical trial, showing improved overall survival
Apr 17, 2026
MIXED
8-K
6/10
Theriva Biologics reported financial results for 2025 and provided corporate updates, including licensing SYN-020 to Ras
Mar 12, 2026
MIXED
Press
6/10
Theriva Biologics reported its 2025 financial results, highlighted by a $9.0 million contingent consideration charge tie
Mar 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $53.7K | DOUBLED |
| MORGAN STANLEY | $42.1K | NEW |
| TWO SIGMA INVESTMENTS, LP | $8.9K | TRIM |
| BANK OF AMERICA CORP | $6.5K | DOUBLED |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
4 institutional holders with $111.2K total value (529,203 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, TWO. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 255,727 | $53.7K | 48.3% | DOUBLED +1461.0% |
| 2 | MORGAN STANLEY | 200,000 | $42.1K | 37.8% | NEW |
| 3 | TWO SIGMA INVESTMENTS, LP | 42,337 | $8.9K | 8.0% | TRIM -31.5% |
| 4 | BANK OF AMERICA CORP /DE/ | 31,139 | $6.5K | 5.9% | DOUBLED +38343.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | DOUBLED | 16,382 | 255,727 | +1461.0% | $53.7K | 2025-Q4 |
| MORGAN STANLEY | NEW | — | 200,000 | — | $42.1K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 61,837 | 42,337 | -31.5% | $8.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 81 | 31,139 | +38343.2% | $6.5K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 61,837 | — | $25.1K | 2025-Q3 |
| UBS Group AG | DOUBLED | 1 | 22,913 | +2291200.0% | $9.3K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 7,851 | 1 | -100.0% | — | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 41 | 74 | +80.5% | $32.00 | 2025-Q2 |
| UBS Group AG | TRIM | 16,406 | 7,851 | -52.1% | $8.6K | 2025-Q1 |
| MORGAN STANLEY | EXIT | 20,200 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | NEW | — | 20,200 | — | $27.9K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 6.5/10.
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$2.50 mean target
+934.3% upside
Strong Buy (3.00)
$1.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $0.2417 |
| Target Low | $1.00 |
| Target Mean | $2.50 |
| Target Median | $2.50 |
| Target High | $4.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.05 | $-0.05 | $-0.05 | 97.4% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.05 | $-0.05 | $-0.05 | 88.9% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.20 | $-0.20 | $-0.20 | 90.4% | +0.0% | 1↑ 0↓ | $0.0B | — | 1 |
| Next FY 2027-12-31 |
$-0.20 | $-0.20 | $-0.20 | 0.0% | +0.0% | 1↑ 0↓ | $0.0B | — | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.050 | |
| 7d ago | $-0.050 | |
| 30d ago | $-0.050 | |
| 60d ago | $-0.210 | +0.160 |
| 90d ago | $-0.210 | +0.160 |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 31, 2026 | Maxim Group | UPGRADE | Hold | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
4 mentions
1 bullish
1 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 28, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 21, 2026 | 2 | 42° Neutral | 0 | 1 | 2 |
| Apr 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
TOVX - Theriva Biologics Inc.
▲ 1
💬 1
⚡ 0.5
TOVX - Theriva Biologics Inc
▲ 1
💬 0
⚡ 0.5
Jun 8, 2026
short_volume
Short Volume: TOVX — 58.9% short (0.4M / 0.6M)
Short: 382,604 | Exempt: 84,557 | TRF Vol: 649,763 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: TOVX — 56.2% short (1.0M / 1.7M)
Short: 955,468 | Exempt: 30,059 | TRF Vol: 1,698,884 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: TOVX — 58.4% short (0.4M / 0.6M)
Short: 360,790 | Exempt: 1,441 | TRF Vol: 617,710 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: TOVX — 64.2% short (0.5M / 0.8M)
Short: 537,663 | Exempt: 0 | TRF Vol: 837,421 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: TOVX — 55.9% short (0.4M / 0.7M)
Short: 416,953 | Exempt: 10,993 | TRF Vol: 745,551 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: TOVX — 71.5% short (1.5M / 2.1M)
Short: 1,496,888 | Exempt: 65,699 | TRF Vol: 2,093,625 | Short Ratio: 71.5% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: TOVX — 63.4% short (0.6M / 0.9M)
Short: 565,375 | Exempt: 139,904 | TRF Vol: 892,159 | Short Ratio: 63.4% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: TOVX — 62.1% short (0.7M / 1.1M)
Short: 682,612 | Exempt: 83,580 | TRF Vol: 1,099,886 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: TOVX — 60.8% short (0.4M / 0.7M)
Short: 431,241 | Exempt: 388 | TRF Vol: 709,748 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings_calendar
TOVX Q1 2026 Earnings Scheduled — 2026-05-12
May 8, 2026
short_volume
Short Volume: TOVX — 65.6% short (0.5M / 0.7M)
Short: 462,683 | Exempt: 505 | TRF Vol: 705,464 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: TOVX — 64.3% short (0.8M / 1.2M)
Short: 761,648 | Exempt: 468 | TRF Vol: 1,184,983 | Short Ratio: 64.3% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
<p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic du
May 4, 2026
short_volume
Short Volume: TOVX — 57.5% short (1.0M / 1.7M)
Short: 963,460 | Exempt: 8 | TRF Vol: 1,674,427 | Short Ratio: 57.5% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: TOVX — 60.9% short (2.3M / 3.7M)
Short: 2,270,115 | Exempt: 21,373 | TRF Vol: 3,728,352 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)